Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
ProQR ( (PRQR) ) just unveiled an announcement.
On April 8, 2026, ProQR Therapeutics hosted a virtual analyst and investor event titled “Expanding the Axiomer RNA Editing Opportunity Beyond AX-0810” to outline progress across its RNA-editing pipeline. Management highlighted AX-0810 as a lead candidate for cholestatic liver diseases, selecting biliary atresia as the initial Phase 2 indication, and presented data supporting NTCP modulation as a strategy to reduce bile acid–driven liver damage.
The company also unveiled two new programs, AX-0811 for cholestatic disease and AX-0422 for Hurler syndrome, alongside plans for AX-2911 in metabolic-associated steatohepatitis, mapping out multiple clinical catalysts through 2027. ProQR emphasized its AI-enabled discovery engine and partnership with Ginkgo as key tools to accelerate Axiomer-based drug discovery, underscoring an ambition to expand its platform and strengthen its position in RNA-editing therapeutics.
The most recent analyst rating on (PRQR) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on ProQR stock, see the PRQR Stock Forecast page.
Spark’s Take on PRQR Stock
According to Spark, TipRanks’ AI Analyst, PRQR is a Neutral.
The score is primarily constrained by weak financial performance—ongoing losses, a return to heavier cash burn, and a declining equity base that increases funding risk. Technicals are moderately supportive in the near term (above short-term moving averages with neutral momentum) but remain challenged longer term (below 100/200-day averages). Valuation is also pressured due to negative earnings and no indicated dividend yield.
To see Spark’s full report on PRQR stock, click here.
More about ProQR
ProQR Therapeutics N.V. is a Netherlands-based biotechnology company focused on developing RNA-editing oligonucleotide therapies using its Axiomer platform. The company is concentrating its clinical pipeline on cholestatic liver diseases and other severe genetic disorders, targeting indications with high unmet medical need such as biliary atresia, primary sclerosing cholangitis and Hurler syndrome.
Average Trading Volume: 427,395
Technical Sentiment Signal: Sell
Current Market Cap: $179.1M
For detailed information about PRQR stock, go to TipRanks’ Stock Analysis page.